首页> 美国卫生研究院文献>Asian Pacific Journal of Cancer Prevention : APJCP >A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

【2h】

A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

机译：Formeta加卡铂作为伊朗晚期非鳞状非小细胞肺癌的一线治疗的IV期功效研究：价格实惠且具有临床益处

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:This study performed to assess the efficacy and safety of Formeta (generic form of Pemetrexed) plus Carboplatin as first-line chemotherapy in advanced stage, non- squamous, non small cell lung cancer (NSCLC) in Iran.

机译：背景：本研究旨在评估Formeta（培美曲塞的通用形式）加卡铂作为一线化疗在伊朗晚期，非鳞状，非小细胞肺癌（NSCLC）中的疗效和安全性。

著录项

期刊名称 Asian Pacific Journal of Cancer Prevention : APJCP
作者
Adnan Khosravi; Babak Salimi; Zahra Esfahani-Monfared; Sharareh Seifi; Hanifeh Mirtavoos-Mahyari;
展开▼
作者单位

展开▼
年(卷),期 2018(19),10
年度 2018
页码 2973–2978
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Non small cell lung cancer carboplatin pemetrexed chemotherapy safety;

机译：非小细胞肺癌;卡铂;培美曲塞;化疗;安全;

相似文献

外文文献
中文文献
专利

1. A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit [J] . Adnan Khosravi, Babak Salimi, Zahra Esfahani-Monfared, Asian Pacific Journal of Cancer Prevention . 2018,第10期

机译：Formeta Plus carboplatin的IV阶段疗效研究作为伊朗前期非鳞状，非小细胞肺癌的一线治疗：临床益处的实惠价格
2. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 [J] . Kanazawa Kenya, Yokouchi Hiroshi, Wang Xintao, Cancer chemotherapy and pharmacology. . 2014,第6期

机译：卡铂和培美曲塞作为一线化疗治疗非鳞状非小细胞肺癌的第二阶段试验，以及与培美曲塞代谢相关的功效/毒性和遗传多态性之间的相关性：北海道肺癌临床研究组试验（HOT）0902
3. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients [J] . Takeoka Hiroaki, Yamada Kazuhiko, Naito Yoshiko, Anticancer Research: International Journal of Cancer Research and Treatment . 2018,第6期

机译：Carboplatin和Pemetrexed Plus贝伐单抗的第二阶段试验与维持贝伐单抗作为老年患者晚期非鳞状非小细胞肺癌的一线治疗
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. A Phase II First-Line Study of Gemcitabine Carboplatin and Bevacizumab in Advanced Stage Non-squamous Non-small Cell Lung Cancer [O] . Christelle Clément-Duchêne, Yelena Krupitskaya, Kristen Ganjoo, -1

机译：吉西他滨卡铂和贝伐单抗在晚期非鳞状非小细胞肺癌中的二期一线研究
7. P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC) [O] . Reynolds Craig, Barrera David, Vu Duy Quoc, 2007

机译：P3-135：针对晚期非鳞状非小细胞肺癌（NSCLC）患者的一线治疗纳米粒结合白蛋白的紫杉醇（nab-紫杉醇），卡铂和贝伐单抗的开放式II期试验的结果

A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

摘要

著录项

相似文献

相关主题

期刊订阅